RXi Pharmaceuticals Aktie
WKN DE: A2JBKM / ISIN: US74979C8082
11.05.2018 13:22:08
|
RXi Pharma Announces Research Collaboration With Iovance Biotherapeutics
(RTTNews) - RXi Pharmaceuticals Corp. (RXII) announced a research collaboration with Iovance Biotherapeutics to evaluate the potential synergies with RXi's sd-rxRNA therapeutic compounds and Iovance's autologous cell therapy based on tumor-infiltrating lymphocytes for the use in the treatment of cancer.
Geert Cauwenbergh, CEO of RXi Pharma, said: "Under this research collaboration, we will further investigate and expand the recently published data with TIL and sd-rxRNA products, which demonstrated potentially enhanced tumor killing activity of TIL."

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu RXi Pharmaceuticals Corp Registered Shsmehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu RXi Pharmaceuticals Corp Registered Shsmehr Analysen
Letzte Top-Ranking Nachrichten
Börse aktuell - Live Ticker
Asiens Börsen im PlusAn den Börsen in Fernost geht es aufwärts.